To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
Status:
Completed
Trial end date:
2021-09-29
Target enrollment:
Participant gender:
Summary
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus,
obesity and nonalcoholic steatohepatitis (NASH) management. This is a first-in-human (FIH),
single-centre, double blind, randomised, SAD and MAD study of XW003 conducted in healthy
adult participants. The study is designed to evaluate the safety, tolerability, PK, and PD of
XW003 in healthy adult participants.